University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 4 of 35
Comparison of Methods for Recording Post Operative Pain
NCT06206148
Emgality for Migraine in Breastmilk
NCT06085144
Bicalutamide Therapy in Young Women With NAFLD and PCOS
NCT05979389
ChangeGradients: Promoting Adolescent Health Behavior Change
NCT04110756
Effect of Group Preoperative Pelvic Floor Training for HoLEP
NCT05719220
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
NCT06097468
Androgens and NAFLD Longitudinal Cohort Study
NCT06124261
PRescription Exercise for Older Men With Urinary Disease
NCT06225479
Wayfinding Intervention and Long-Term Memory
NCT05625425
Genomic Sequencing in Anatomically Normal Fetuses
NCT06211348
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT05964504
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
NCT05766371
Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT06171139
Effect of Ketamine on Intraoperative Motor Evoked Potentials
NCT06140927
The Heart Health After Cardiac Treatment Study
NCT07158515
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
NCT05933083
Valacyclovir in Pain Management of Acute Apical Abscesses
NCT05266040
PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery
NCT06089083
Correction of Psoriatic T Cell Signatures by Deucravacitinib
NCT05858645
Preschool Hearing Screening
NCT06058767
Investigating the Use of Intravenous Tranexamic Acid in Gender Affirming Mastectomy
NCT05794321
Recovery Trajectory for Coma and Disorders of Consciousness
NCT07614074
Melanin and Dermal Uptake of Thirdhand Cigarette Smoke
NCT06020248
Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures
NCT06030674
UPURS Trial for Patient-centered Management of Symptomatic Obstructing Stones
NCT05715086
Patient Care Outreach, Navigation, Technology and Support 2.0
NCT06648278
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
NCT05851391
Chronic Thromboembolic Disease Registry
NCT05843500
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
NCT05359653
TabCAT Brain Health Assessment in Primary Care
NCT06090578
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
NCT05478837
Exercise for Cognitive Excellence in Parkinson's Disease
NCT05720468
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
NCT05746208
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
NCT05606237
Immune Spatial Features of Guselkumab Cutaneous Response
NCT05858632
Complex And Simple Appendicitis: REstrictive or Liberal Post-operative Antibiotic eXposure - UCSF
NCT05966454
Combination Therapy in Cancers With Mutations in DNA Repair Genes
NCT05694715
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
NCT05902507
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
NCT05746182
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
NCT05757583
HEalth Advocate for Liver Transplant - Pilot
NCT05700799
PrehabPal: A Digital Tool to Help Older Adults Prepare for Cancer Surgery
NCT05520866
Lemborexant in Delayed Sleep Phase Syndrome
NCT06874855
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
NCT05642858
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
NCT05818605
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
NCT05658471
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
NCT05572632
Risk Indicators of Sarcoidosis Evolution-Unified Protocol
NCT05567133
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
NCT05530317
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets.Report a data error.